Immediate pharmacotherapy intensification after cardiac resynchronization therapy: incidence, characteristics, and
Kojiro Ogawa1, Hiro Yamasaki1, Kazutaka Aonuma1
1Department of Cardiology, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.
Insights
Immediate intensification of heart failure medication after cardiac resynchronization therapy improves patient outcomes. This strategy significantly reduces mortality and hospitalizations for heart failure in eligible patients.
Area of Science:
- Cardiology
- Medical Devices
- Pharmacology
Background:
- Cardiac resynchronization therapy (CRT) is a key treatment for drug-refractory heart failure (HF) in patients with left bundle branch block (LBBB).
- Acute hemodynamic improvements post-CRT may allow for expedited intensification of HF medications.
- Immediate pharmacotherapy intensification (IPI) could offer synergistic benefits and improve prognosis.
Purpose of the Study:
- To investigate the incidence and characteristics of IPI in CRT recipients with prior acute HF hospitalizations.
- To evaluate the real-world impact of IPI on clinical outcomes in this patient population.
Main Methods:
- A multicenter retrospective study of 194 CRT recipients with LBBB, QRS width ≥120 ms, LVEF ≤35%, and NYHA II-IV symptoms, all with recent HF hospitalizations.
- IPI defined as intensification of guideline-directed medical therapy (beta-blockers, ACE inhibitors/ARBs, MRAs) within 30 days of CRT.
- Primary endpoint: all-cause death or HF hospitalization; Secondary endpoint: all-cause death. Median follow-up: 29 months.
Main Results:
- 54% of patients received IPI. IPI patients had shorter QRS duration, higher eGFR, and more dilated cardiomyopathy.
- IPI was associated with significantly better outcomes for both primary and secondary endpoints.
- IPI was an independent predictor of a reduced primary endpoint (HR 0.51; 95% CI 0.27-0.97; P=0.043).
Conclusions:
- Immediate pharmacotherapy intensification is feasible in over half of CRT recipients, particularly those without excessive QRS prolongation, with preserved renal function, and dilated cardiomyopathy.
- IPI in LBBB patients undergoing CRT is linked to a significantly better prognosis and reduced HF hospitalizations.
Aims:
Cardiac resynchronization therapy (CRT) is an established treatment for drug-refractory heart failure (HF) in patients with left bundle branch block (LBBB). Acute haemodynamic improvement after CRT implantation may enable the intensification of HF medication soon thereafter. Immediate pharmacotherapy intensification (IPI) after CRT implantation achieves a synergetic effect, possibly leading to a better prognosis. This study aimed to explore the incidence, characteristics, and impact of IPI on real-world outcomes among CRT recipients with a history of hospitalization for acute HF.
Methods And Results:
This multicentre retrospective study enrolled CRT recipients with LBBB morphology, a QRS width ≥120 ms, a left ventricular ejection fraction ≤35%, and New York Heart Association II-IV HF symptoms. All patients had previous HF hospitalizations within the previous year and received guideline-directed medical therapy before CRT implantation. Patient baseline characteristics, including HF medication, were collected. IPI was defined as the intensification of beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and mineralocorticoid receptor antagonists within 30 days of CRT implantation. The primary endpoint was all-cause death or first hospitalization for HF; the secondary endpoint was all-cause death. We enrolled 194 patients (75% male; mean age, 65 ± 13 years; 78% with non-ischaemic cardiomyopathy). One hundred five (54%) patients received IPI. Patients who received IPI exhibited a significantly shorter QRS duration (159 ± 26 vs. 171 ± 32 ms; P = 0.004), higher estimated glomerular filtration rate (55.2 ± 20.0 vs. 47.8 ± 24.7 mL/min/1.73 m2; P = 0.022), and more dilated cardiomyopathy. During a median follow-up period of 29 months, 70 (36%) patients reached the primary endpoint and 42 (22%) patients died. Patients with IPI showed significantly better outcomes for the primary and secondary endpoints than patients without IPI. The volumetric responder ratio at 6 months after implantation was not significantly different between patients with and without IPI; however, patients who received IPI had reduced mortality even at 6 months after implantation. In the multivariate analysis, IPI was an independent predictor of the primary endpoint (hazard ratio, 0.51; 95% confidence interval, 0.27-0.97; P = 0.043).
Conclusions:
Immediate intensification of HF medication was achieved in 54% of CRT recipients and was significantly higher in patients without excessive QRS prolongation, preserved renal function, and dilated cardiomyopathy than others. In patients with LBBB morphology and QRS ≥ 120 ms, IPI was associated with a significantly better prognosis and fewer HF hospitalizations after CRT implantation than others.
Related Concept Videos
01:26Heart Failure Drugs: Inotropic Agents
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:20Desensitization and Tachyphylaxis